So just to summarize what I've been saying about peripheral peripheral T cell lymphoma, it's a fascinating condition, it's rare. Uh, so therefore it's quite hard to study, particularly in randomized, uh, clinical trials. Outcomes with first line treatments, such as with CHOP or COEP or BV CHP, are generally poor, with less than 50%, uh, durable responses and therefore cures. Um, some patients may try and increase that with an autologous stem cell transplant, but even so, uh, cure rates are relatively low, certainly compared with B cell non-Hodgkin lymphomas. Treatment at relapse generally consists, at least in Europe and the UK of second line chemotherapy, uh, potentially, uh, with access to Brenttuximabbidotin or lenalidomide, but really we don't expect a high rate of response, sadly with those agents, and certainly those responses are not generally considered durable or curative. There may be younger or fitter patients we can use second line chemotherapy to bridge them to an alloy stem cell transplant. So this really leads to a desperate, uh, and really very urgent unmet need for these patients. A number of molecularly targeted agents are coming through, and some of these seem to have preferential activity in different subtypes of PTCL. One of these is the PI3 kinase inhibitor Duvaliib, studied so far in the phase two study. Primo, showing that in the AITL cohort, there's a response rate of over 50%. Uh, and a progression free survival of over 8 months, which is certainly very very potentially very meaningful, uh, in this population. And so this is now being taken forward and studied in the relapsed refractory setting of the TFH derived, uh, peripheral T cell lymphomas in the Turzo study, randomized 1 to 1 juvalicip compared with either gem cytopine or bendomustin, and that trial is now open in both Europe and the UK.
Presenter
